Preventing, identifying and treating infectious diseases has been a hot spot for innovation in healthcare. This growing company, though, is taking a step back, focusing instead on improving the process of physically getting a specimen sample to a place where it can be tested for these diseases. ViveBio LLC, which makes a dried biological specimen […]
The technician was indicated Wednesday in New Hampshire on 14 new charges. The outbreak involved more than 30 patients in New Hampshire while people in a number of other states were exposed. The New York Times: Medical Technician Accused In Hepatitis C...
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A clinical-stage biopharmaceutical company developing drug candidates for hepatitis D and hepatitis C has secured $4.6 million of its targeted $5 million funding round.
GlaxoSmithKline (NYSE:GSK) now wants approval to use its low platelet drug Promacta to treat hepatitis C patients. GSK has filed regulatory applications in Europe and the United States to add the new indication to the drug. The drug eltrombopag, which is marketed under the brand name Promacta in the United States and Revolade globally, is […]
Drug discovery and development company Scynexis, which is in midstage clinical development of a novel hepatitis C treatment, is getting closer to reaching its $15 million fundraising target. Scynexis has raised nearly $11.5 million so far, according to an amended securities filing. The fundraiser, a mix of equity, debt, options and warrants, launched in December. […]
The hepatitis C virus is believed to have links to the growth of liver cancer, but those connections have been hard to study. University of North Carolina at Chapel Hill research aimed at learning more about those connections has secured a $2.35 million federal grant. The five-year grant from the National Cancer Institute will enable […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Every week, MedCity news highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCityNews.com. Now here's the best of what YOU had to say.
The experimental hepatitis C treatment that BioCryst Pharmaceuticals (NASDAQ:BCRX) wants to take into clinical trials this year has run into an unexpected hitch: a patent for the compound was awarded to another pharmaceutical company. Biota was granted the patent in “an apparent error,” BioCryst said in a March 12 securities filing. The Feb. 21 patent […]
Life sciences companies presenting at CED’s Life Science Conference largely stuck to script. Prepared remarks. PowerPoint presentations. After 11 minutes on stage, another presenter took their place. Immunotherapy company Heat Biologics broke from script and announced a $10 million series B round to complete one mid-stage study on its lead treatment candidate and two early […]
The investigational hepatitis C treatment under development by BioCryst Pharmaceuticals (NASDAQ:BCRX) is now ready to move into human studies following positive preclinical trial results released today. BioCryst expects to file an investigational new drug application on the compound BCX5191 in the fourth quarter. BioCryst believes BCX5191 can be developed into a drug with once-a-day dosing […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Current medical news from today, including hepatitis C developers rise as BMY acquires Inhibitex, Bayer to open incubator, and Novartis recalls popular drugs.
Drug discovery startup NovaTarg is ramping up preclinical research in preparation of an expected investigational new drug application filing for the company’s first drug candidate — a new hepatitis C treatment . The Research Triangle Park, North Carolina-based company now has a $30,000 loan from the North Carolina Biotechnology Center to help its efforts. The […]
Drug discovery and development firm Scynexis, which is moving forward on a new hepatitis C treatment, has raised $5 million in a fundraising effort targeted to reach up to $15 million. A total of nine investors have invested in the round that is a combination of equity, debt, warrants and options, according to securities filings. […]
Inovio Pharmaceuticals (NYSE AMEX: INO) has teamed up with affiliate VGX International to finance clinical development of the Blue Bell, Pennsylvania-based drug developer’s therapeutic vaccines for hepatitis B and C infections. Under the terms of the deal, VGX will receive marketing rights for the vaccines in Asia, but Inovio will hold onto the lucrative Japanese […]